KALA BIO, Inc. (KALA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 4, 2025, details a material definitive agreement entered into by KALA BIO, Inc. The company, incorporated in Delaware and trading on the Nasdaq Capital Market, announced a registered direct offering that closed on December 5, 2025.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $10 million from the offering.
- Securities Issued: 900,000 shares of Common Stock and pre-funded warrants to purchase up to 9,100,000 shares.
- Purchase Price: $1.00 per share (Common Stock) and $0.9999 per pre-funded warrant.
- Transaction Costs: 8.0% cash fee to the placement agent (H.C. Wainwright & Co., LLC), plus $50,000 for legal fees and $15,950 for clearing expenses.
- Use of Proceeds: Repayment of certain indebtedness and general corporate purposes.
Note: This filing does not provide specific values for revenue, profit, cash flow, margins, or total debt levels outside of the stated intent to repay certain indebtedness.
Material Changes and Transaction Structure
The company executed a securities purchase agreement with an institutional investor. The transaction structure includes:
- Pre-Funded Warrants: Initial exercise price of $0.0001, exercisable at any time until fully exercised.
- Ownership Caps: Holders are restricted from exercising warrants if it would cause beneficial ownership to exceed 4.99% (or 9.99% upon election) of outstanding shares, subject to notice provisions for increases.
- Issuance Restrictions: The company is restricted from issuing Common Stock or equivalents for 30 days post-closing and cannot engage in Variable Rate Transactions for one year.
Outlook, Risks, and Management Commentary
Management indicated the primary strategic use of the net proceeds is to reduce existing debt obligations. The filing references customary representations, warranties, and indemnification provisions. No specific forward-looking guidance regarding revenue or earnings was provided in this document. The primary risk associated with this transaction is the dilution of existing shareholders due to the issuance of 10 million total shares (900,000 common + 9,100,000 warrant shares).
Key Facts for Investor Verification
- Verify the specific amount of indebtedness intended to be repaid with the $10 million gross proceeds.
- Confirm the current total share count to calculate the precise dilution impact of the 10 million new shares.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for detailed covenants and restrictions.
- Monitor the company's cash position post-closing to assess liquidity improvements.